Alluvi, formerly BI 4744, presents a promising breakthrough in weight management therapy. This dual stimulator targeting both glucagon-like peptide-1 and GIP targets demonstrates remarkable efficacy in research https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/